Glycosylated Lymphotoxin Inhibits Tumor Growth in Mice
Author Information
Author(s): I. Funahashi, H. Watanabe, T. Abo, K. Indo, H. Miyaji
Primary Institution: Hyogo College of Medicine and Niigata University School of Medicine
Hypothesis
The study investigates the antitumor effects of glycosylated recombinant human lymphotoxin (gLT) compared to nonglycosylated lymphotoxin (LT) and TNF in mice.
Conclusion
Glycosylated lymphotoxin shows significant antitumor activity in mice, primarily due to its longer serum half-life and the involvement of specific immune cells.
Supporting Evidence
- The systemic administration of gLT showed significant antitumor activity.
- The serum half-life of gLT was 3-fold longer than that of nonglycosylated LT.
- Mononuclear cells in the tumor tissues were predominantly IL-2 receptor + /CD3 - cells and CD3 + cells.
- Treatment with gLT produced a significant reduction in numbers of tumor-regional mononuclear cells.
Takeaway
This study found that a special type of lymphotoxin can help stop tumors from growing in mice, and it works better because it stays in the body longer.
Methodology
Mice were treated with glycosylated LT, nonglycosylated LT, and TNF, and tumor growth was measured over time.
Limitations
The study primarily used mice, which may not fully represent human responses.
Participant Demographics
Female BALB/c and BALB/c nu/nu mice, aged 6 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website